Companies Dominating the Atrial Fibrillation Surgery Landscape
- Abbott Laboratories.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- AtriCure, Inc.,
- Biosense Webster, Inc.,
- Boehringer Ingelheim GmbH
- Boston Scientific Corporation
- Bristol-Myers Squibb Corporation
- CardioFocus, Inc.,
- Endoscopic Technologies, Inc.,
- Sanofi Aventis,
- Johnson and Johnson Ltd.,
Browse Key Market Insights with Data Illustration:
In the News
- physIQ, which uses wearable biosensor data to generate personalized, clinically valid, actionable insights announced a strategic collaboration with InCarda Therapeutics, Inc., and a privately-held, clinical-stage biopharmaceutical company developed inhaled therapies for cardiovascular diseases. In patients with atrial fibrillation, this collaboration is intended to speed up the Phase III study.
- Abbott reported positive results from the PERSISTEND study of its TactiCath Contact Force Ablation Catheter, Sensor Enabled, in May 2022. (TactiCath SE) for persistent atrial fibrillation (AFib), the most common arrhythmia
